GLP1R and atrial fibrillation: A high-quality meta-analysis of randomized controlled trials by Boulmpou et al. found that GLP-1 RA treatment did not significantly reduce the risk of atrial fibrillation (AF), atrial flutter, ventricular fibrillation, ventricular tachycardia, sinus node dysfunction, ventricular extrasystoles, second-degree atrioventricular block, or complete atrioventricular block [126].